At Abington Neurological Associates we are committed to offering cutting edge treatments for our patients. Clinical trials are available in many different areas. Please contact our Clinical Trials Research Office if you are interested in learning more information about any of the trials that we offer at (215) 957-9250.

Additional information about these trials can be found at www.clinicaltrials.gov using the Clinical Trials.gov Identifier code provided after each study title.

Alzheimer's/Mild Cognitive Impairment Studies

  • A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Proof-of- Concept, Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer’s Disease (Prodromal Alzheimer’s Disease) and Mild to Moderate Dementia Due to Alzheimer’s Disease ID# NCT02322021
  • A Phase III, Randomized, Placebo – Controlled, Parallel – Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 (SCH 900931) in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer’s Disease (Prodromal AD). ID# NCT01953601
  • The Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) Study will establish an open-label, longitudinal cohort study to assess the impact of amyloid PET on patient outcomes under Coverage with Evidence (CED) in patients meeting Appropriate Use Criteria (AUC) for amyloid PET (Johnson et al. 2013) ID# NCT02420756
  • A Placebo – Controlled, Double-Blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen – finding Study To Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects with Early Alzheimer’s Disease. ID# NCT01767311
  • A Phase 3, Multicenter, Long-term, Extension Study of the Safety and Efficacy of AVP-786 (deuterated [d6] dextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for theTreatment of Agitation in Patients with Dementia of the Alzheimer’s Type ID# NCT02446132
  • AC-12-010: A 26 – Week, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants with Mild to Moderate Alzheimer’s Disease (AD), with an Optional 26 – Week Open-Label Extension. ID# NCT01741194
  • A Phase 3, Double-blind, Randomized Study of RVT-101 Versus Placebo When Added to Existing Stable Donepezil Treatment in Subjects With Mild to Moderate Alzheimer's Disease ID# NCT02585934

Stroke - TIA Studies

  • Platelet – Oriented Inhibition in New TIA or Minor Stroke (POINT). ID# NCT00991029
  • Stroke Hyperglycemia Insulin Network Effort (SHINE). ID# NCT01369069
  • Randomized, Double-blind, Evaluation in Secondary Stroke Prevention Comparing the EfficaCy and Safety of the Oral Thrombin Inhibitor Dabigatran Etexilate (110 mg or 150 mg, Oral b.i.d.) Versus Acetylsalicylic Acid (100 mg Oral q.d.) in Patients With Embolic Stroke of Undetermined Source (RESPECT ESUS) ID# NCT02239120

Parkinson's Disease Studies

  • A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of CVT 301 (Levodopa Inhalation Powder) in Parkinson's Disease Patients With Motor Response Fluctuations (OFF Phenomena) (SPAN-PD ™) ID# NCT02240030
  • A 12 Month, Dose-Level Blinded Study Investigating the Safety and Efficacy of CVT 301 (Levodopa Inhalation Powder) in Parkinson's Disease Patients With Motor Response Fluctuations (OFF Phenomena) ID# NCT02242487

Multiple Sclerosis Studies

  • A Multicenter, Global, Observational Study to Collect Information on Safety and to Document the Drug Utilization of Tecfidera (Dimethyl Fumarate) When Used in Routine Medical Practice in the Treatment of Multiple Sclerosis (ESTEEM). ID# NCT02047097
  • A Placebo – Controlled, Randomized, Withdrawal Evaluation the Efficacy and Safety of Baclofen ER Capsules (GRS) in Subjects with Spasticity due to Multiple Sclerosis. (CLR_09_21). ID# NCT01457352
  • Long-term, Prospective, Multinational, Parallel-cohort Study Monitoring Safety in Patients With MS Newly Started With Fingolimod Once Daily or Treated With Another Approved Disease-modifying Therapy ID# NCT01442194
  • This multicenter, randomized, open-label study will evaluate the immune response to vaccines (tetanus toxoid [TT], 23-valent pneumococcal polysaccharide vaccine [23-PPV], influenza vaccine, and keyhole limpet hemocyanin [KLH]) after administration of a dose of ocrelizumab (OCR) in participants with relapsing multiple sclerosis (RMS). ID# NCT02545868

Chronic Regional Pain Syndrome

  • A Randomized, Double-blind Trial Investigating the Efficacy and Safety of Intravenous Neridronic Acid in Subjects With Complex Regional Pain Syndrome Type I (CRPS-I) ID# NCT02402530

Headache/Migraine Trials

  • A phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY295142 in Patients with Episodic Migraine. ID# NCT02614183
  • A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study ID# NCT02614261